ARIA

Cerebrolysin

Not FDA Approved✓ WADA Permitted

CBL / Neurotrophic peptide mixture

neuroprotectionClinical EvidenceNeurotrophic peptide complex (pig brain derived)

Mixture of neurotrophic peptides and amino acids. Approved in Europe/Asia for stroke, dementia, TBI. Crosses BBB. Not FDA-approved but available through specialty pharmacies.

Confidence
68%
Half-Life ~hours
Cost ~$600/mo
Quick Reference
Routeintravenous
MechanismMimics endogenous neurotrophic factors (NGF, BDNF, GDNF). Induces neurogenesis, ...
SequencePEPTIDE_MIXTURE
Reviewed2026-07-08

Mechanism of Action

Mimics endogenous neurotrophic factors (NGF, BDNF, GDNF). Induces neurogenesis, neuroplasticity, neuroprotection. Reduces neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.

Dosing Protocol

10-30mL IV daily or every other day. Cycles of 20-30 days, 2-3x/year.

Key Studies

2025

Cerebrolysin vascular dementia

PMID 39832667review
2024

Cerebrolysin motor recovery post-stroke

PMID 39580783preclinical

Adverse Effects

DizzinessHeadacheInjection site reactionsRare hypersensitivity

Contraindications

  • Severe renal impairment
  • Epilepsy
  • Pregnancy

Storage

Refrigerate at 2-8°C. Do not freeze. Protect from light.

Clinical Applications

  • ["neuroprotection"
  • "cognitive_support"
  • "anti_aging"]